Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Trails Edge Capital Partners, LP
Form 13F · Q2 2026

Trails Edge Capital Partners, LP

CIK 2077247Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$630M
Reported book value
35
Positions
3
Quarters on record
Top 50
Positions

Trails Edge Capital Partners, LP — holdings

Top 35 positions of 35, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1LBRX Lb Pharmaceuticals Inc1.5M+15.4%$49M7.8%
2NRIX Nurix Therapeutics Inc1.6M−9.8%$38M6.1%
3IMCR Immunocore Hldgs Plc1.1M+55.8%$34M5.4%
4TRAX First Tracks Biotherapeutics1.5M—$30M4.8%
5FDMT 4D Molecular Therapeutics In2.2M+71.0%$30M4.7%
6BMRN Biomarin Pharmaceutical Inc512,000—$29M4.7%
7DSGN Design Therapeutics Inc2.0M+134.9%$29M4.6%
8XENE Xenon Pharmaceuticals Inc440,000+0.0%$27M4.2%
9MIRM Mirum Pharmaceuticals Inc223,312−33.0%$26M4.2%
10INSM Insmed Inc230,331—$25M3.9%
11CYTK Cytokinetics Inc288,089−4.0%$25M3.9%
12SNDX Syndax Pharmaceuticals Inc1.1M+58.2%$24M3.9%
13NGNE Neurogene Inc714,885−8.7%$22M3.6%
14KLRA Kailera Therapeutics Inc984,786—$22M3.4%
15RVMD Revolution Medicines Inc115,750−52.8%$22M3.4%
16IKT Inhibikase Therapeutics Inc9.1M+12.3%$18M2.9%
17INCY Incyte Corp155,000—$18M2.8%
18AVTX Avalo Therapeutics Inc891,881—$16M2.6%
19MLTX Moonlake Immunotherapeutics750,000—$15M2.3%
20FTH Faeth Therapeutics Inc515,335+312.3%$13M2.0%
21XFOR X4 Pharmaceuticals Inc2.6M+0.0%$12M1.9%
22IRD Opus Genetics Inc2.7M+448.7%$11M1.8%
23SLGL Sol-Gel Technologies Ltd139,445+63.1%$10M1.6%
24AURA Aura Biosciences Inc1.4M—$10M1.6%
25IPSC Century Therapeutics Inc4.1M+68.8%$10M1.6%
26IVA Inventiva Sa2.7M+0.0%$10M1.6%
27CAMP Camp4 Therapeutics Corp1.9M−0.3%$8M1.3%
28ALT Altimmune Inc2.7M—$8M1.3%
29NERV Minerva Neurosciences Inc1.4M+0.0%$8M1.3%
30PMN Promis Neurosciences Inc557,103+0.0%$7M1.2%
31OKUR Onkure Therapeutics Inc1.4M—$7M1.0%
32FORTE BIOSCIENCES INC Forte Biosciences Inc273,181—$6M0.9%
33RACC Research Alliance Corp Iii500,000—$5M0.8%
34VTVT Vtv Therapeutics Inc85,192−39.0%$3M0.5%
35IMA Imagenebio Inc282,004—$2M0.3%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.